Eagle Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Eagle Pharmaceuticals generated cash of $30,797,000, which is less than the previous year. Cash used in financing activities reached the amount of $0 last year. Net change in cash is therefore $30,797,000.
Cash Flow
| 2014 | -13.84M | -20.04M | 46.15M |
|---|---|---|---|
| 2015 | -9.71M | -1.88M | 55.81M |
| 2016 | 53.20M | -45.8M | -33.67M |
| 2017 | 58.91M | -5.18M | 8.10M |
| 2018 | 52.38M | -133K | -88.11M |
| 2019 | 55.98M | -777K | -24.22M |
| 2020 | 49.49M | -18.24M | -37.87M |
| 2021 | 28.21M | -5.32M | -28.39M |
| 2022 | 50.70M | -86.83M | -6.20M |
| 2023 | 30.79M | 0 | 0 |
EGRX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 0 | 97.65M | 103.15M | 109.77M | 78.79M | 114.65M | 52.82M | 79.08M | 34.86M | 10.45M |
Operating activities | ||||||||||
Net income | -2.66M | 35.64M | -8.62M | 11.98M | 14.31M | 31.90M | 51.94M | 81.45M | 2.57M | -17.97M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 16.66M | 12.02M | 3.76M | 4.76M | 4.65M | 3.67M | 3.74M | 1.58M | 112K | 104K |
Stock-based compensation expense | 0 | 16.45M | 19.55M | 24.75M | 21.99M | 0 | 15.42M | 9.76M | 4.05M | 606K |
| Deferred income tax benefit | 0 | 16.45M | 19.55M | 24.75M | 21.99M | 0 | 15.42M | 9.76M | 4.05M | 606K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | -30.83M | 9.52M | -3.11M | 18.48M | -12.66M | -11.62M | -15.91M | -14.31M | -2.17M |
Inventories | 866K | -8.33M | -13.83M | -1.50M | 1.73M | -5.55M | -2.37M | 12.30M | -13.8M | -1.29M |
Accounts payable | 0 | 2.96M | 10.16M | 806K | -4.45M | -2.06M | -8.46M | 10.66M | 356K | 2.86M |
Cash generated by operating activities | 30.79M | 50.70M | 28.21M | 49.49M | 55.98M | 52.38M | 58.91M | 53.20M | -9.71M | -13.84M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | -12.5M | 0 | -17.5M | 0 | 0 | 0 | -62M | -105.99M | -19.99M |
Investments In Property Plant And Equipment | 0 | -178K | -323K | -747K | -777K | -133K | -5.18M | -20.69M | -1.88M | -46K |
Acquisitions Net | 0 | -74.15M | 0 | 0 | 0 | 0 | 0 | -26.86M | 0 | 0 |
Cash generated by investing activities | 0 | -86.83M | -5.32M | -18.24M | -777K | -133K | -5.18M | -45.8M | -1.88M | -20.04M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 2.39M | 3.65M | 0 | 8.61M | 0 | 3.61M | 54.33M | 46.06M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -18.00M | -21.21M | -34.99M | -17.96M | -73.10M | -43.79M | -37.00M | 0 | 0 |
Repayments of term debt | 0 | 12.76M | -8M | -115M | -6M | -3.75M | 48.75M | 0 | 0 | 0 |
Cash used in financing activities | 0 | -6.20M | -28.39M | -37.87M | -24.22M | -88.11M | 8.10M | -33.67M | 55.81M | 46.15M |
Net Change In Cash | 30.79M | -42.33M | -5.49M | -6.62M | 30.98M | -35.86M | 61.83M | -26.26M | 44.21M | 12.26M |
Cash at end of period | 30.79M | 55.32M | 97.65M | 103.15M | 109.77M | 78.79M | 114.65M | 52.82M | 79.08M | 22.72M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |